ECSP088829A - Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1) - Google Patents

Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)

Info

Publication number
ECSP088829A
ECSP088829A EC2008008829A ECSP088829A ECSP088829A EC SP088829 A ECSP088829 A EC SP088829A EC 2008008829 A EC2008008829 A EC 2008008829A EC SP088829 A ECSP088829 A EC SP088829A EC SP088829 A ECSP088829 A EC SP088829A
Authority
EC
Ecuador
Prior art keywords
bencimidazol
cannabinoid
receptor ligands
sulfonamide derivatives
compounds
Prior art date
Application number
EC2008008829A
Other languages
English (en)
Inventor
Christopher Simon John Walpole
William Brown
Ziping Liu
Daniel Page
Zena Qadoumi
Sanjay Srivastava
Maxime Tremblay
Zhong-Yong Wei
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088829A publication Critical patent/ECSP088829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula I o sales farmacéuticamente aceptables de la misma: Donde R1, R2, R3, y R4 son tal como se definen en la descripción así como sales y composiciones farmacéuticas incluyendo los compuestos como se preparan. Son útiles en terapia, principalmente en el manejo del dolor.
EC2008008829A 2006-04-18 2008-10-17 Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1) ECSP088829A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74501106P 2006-04-18 2006-04-18

Publications (1)

Publication Number Publication Date
ECSP088829A true ECSP088829A (es) 2008-11-27

Family

ID=38609783

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008829A ECSP088829A (es) 2006-04-18 2008-10-17 Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)

Country Status (19)

Country Link
US (1) US7615642B2 (es)
EP (1) EP2010526A4 (es)
JP (1) JP2009534379A (es)
KR (1) KR20080109936A (es)
CN (1) CN101472917A (es)
AR (1) AR060472A1 (es)
AU (1) AU2007239102B8 (es)
BR (1) BRPI0709625A2 (es)
CA (1) CA2649287A1 (es)
CO (1) CO6140035A2 (es)
EC (1) ECSP088829A (es)
IL (1) IL194393A0 (es)
MX (1) MX2008013040A (es)
NO (1) NO20084785L (es)
RU (1) RU2008139479A (es)
TW (1) TW200808769A (es)
UY (1) UY30289A1 (es)
WO (1) WO2007120101A1 (es)
ZA (1) ZA200808692B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
CA2654246A1 (en) * 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
WO2010147791A1 (en) * 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
CA2768832A1 (en) * 2009-07-23 2011-01-27 Vanderbilt University Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CN104140427A (zh) * 2014-07-05 2014-11-12 湖南华腾制药有限公司 一种四氢吡唑并[1,5-a]嘧啶的制备方法
FR3030516B1 (fr) * 2014-12-19 2019-12-27 Galderma Research & Development Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
EP3814337A1 (en) * 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB955961A (en) * 1959-09-24 1964-04-22 Gevaert Photo Prod Nv Benzimidazole derivatives
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (es) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
BR9612434A (pt) * 1995-12-28 1999-12-28 Fujiwasa Pharmaceutical Co Ltd Derivados de benzimidazol
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001019798A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics Inc. INHIBITORS OF FACTOR Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
MXPA02005742A (es) 2000-01-14 2002-09-18 Schering Ag 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia.
WO2001064643A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AU2002221239A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006012642A2 (en) 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
US20060052421A1 (en) * 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
WO2006033633A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
JP2008514590A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
WO2006033632A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
WO2006033630A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
AU2005287427B2 (en) 2004-09-24 2009-03-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof I
JP2008514591A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
JP2008514589A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉｉ
MX2007005290A (es) * 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
UY30289A1 (es) 2007-11-30
JP2009534379A (ja) 2009-09-24
CA2649287A1 (en) 2007-10-25
ZA200808692B (en) 2009-07-29
AU2007239102B8 (en) 2011-08-11
EP2010526A4 (en) 2011-06-22
US20070244092A1 (en) 2007-10-18
NO20084785L (no) 2009-01-09
AR060472A1 (es) 2008-06-18
KR20080109936A (ko) 2008-12-17
IL194393A0 (en) 2009-08-03
WO2007120101A1 (en) 2007-10-25
BRPI0709625A2 (pt) 2011-07-19
RU2008139479A (ru) 2010-05-27
AU2007239102A1 (en) 2007-10-25
CO6140035A2 (es) 2010-03-19
TW200808769A (en) 2008-02-16
AU2007239102B2 (en) 2011-07-07
CN101472917A (zh) 2009-07-01
MX2008013040A (es) 2008-10-17
EP2010526A1 (en) 2009-01-07
US7615642B2 (en) 2009-11-10

Similar Documents

Publication Publication Date Title
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
MX2010001574A (es) Ligandos del receptor cannabinoide.
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY28537A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UY30412A1 (es) Derivados de las 1-([1h-benzimidazol-5il]carbonil)-piperidin-carboxamidas n-sustituidas, composiciones farmacéuticas conteniéndolos, proceso de preparacion y aplicaciones